Perrigo (PRGO) Competitors

Perrigo (NYSE:PRGO) and Corcept Therapeutics (NASDAQ:CORT) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, community ranking, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

Which has more volatility and risk, PRGO or CORT?

Perrigo has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500.

Do analysts rate PRGO or CORT?

Perrigo presently has a consensus price target of $33.00, indicating a potential upside of 19.59%. Corcept Therapeutics has a consensus price target of $138.25, indicating a potential upside of 91.30%. Given Corcept Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Corcept Therapeutics is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Corcept Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders & institutionals have more ownership in PRGO or CORT?

95.9% of Perrigo shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 0.7% of Perrigo shares are owned by insiders. Comparatively, 20.8% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Does the media favor PRGO or CORT?

In the previous week, Corcept Therapeutics had 9 more articles in the media than Perrigo. MarketBeat recorded 17 mentions for Corcept Therapeutics and 8 mentions for Perrigo. Perrigo's average media sentiment score of 0.93 beat Corcept Therapeutics' score of 0.22 indicating that Perrigo is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is PRGO or CORT more profitable?

Corcept Therapeutics has a net margin of 22.35% compared to Perrigo's net margin of -3.64%. Corcept Therapeutics' return on equity of 24.54% beat Perrigo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-3.64%	7.38%	3.18%
Corcept Therapeutics	22.35%	24.54%	20.24%

Does the MarketBeat Community prefer PRGO or CORT?

Perrigo received 224 more outperform votes than Corcept Therapeutics when rated by MarketBeat users. However, 71.26% of users gave Corcept Therapeutics an outperform vote while only 66.38% of users gave Perrigo an outperform vote.

Company	Underperform	Outperform
Perrigo	Outperform Votes 772 66.38%	Underperform Votes 391 33.62%
Corcept Therapeutics	Outperform Votes 548 71.26%	Underperform Votes 221 28.74%

Which has higher earnings and valuation, PRGO or CORT?

Corcept Therapeutics has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.34B	0.88	-$12.70M	-$1.31	-21.06
Corcept Therapeutics	$685.45M	11.18	$106.14M	$1.16	62.30

Summary

Corcept Therapeutics beats Perrigo on 13 of the 18 factors compared between the two stocks.